WELL Health and Healwell AI are Buys, Stifel Says
Stifel analyst Justin Keywood maintained that both WELL Health Technologies and Healwell AI stand to benefit from structural changes within the healthcare system.
Keywood said in an Oct. 9 conference recap that both companies remain compelling long-term healthcare technology plays, each positioned to benefit from sector consolidation and ongoing digital transformation across Canada’s strained healthcare system.
- WELL Health Technologies: “Buy” rating and C$9.00 target
- Healwell AI: “Buy” rating and C$3.80 target
WELL “continues to streamline its structure and focus on core assets,” including an expected U.S. expansion
Author's summary: Stifel recommends buying WELL and Healwell AI stocks.